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DIntroduction: The frequency and successful use of pediatric ventricular assist devices (VADs) as a bridge to
cardiac transplantation have been steadily increasing since 2003, but the experience in patients with complex
congenital heart disease has not been well described. Using a large prospectively collected dataset of children
supported with the Berlin Heart EXCORVAD, we have reviewed the experience in children with single ventric-
ular anatomy or physiology (SV), and compared the results with those supported with biventricular circulation
(BV) over the same time period.
Methods: The EXCOR Investigational Device Exemption study database was retrospectively reviewed. VAD
implants under the primary cohort and compassionate use cohort between May 2007 and December 2011
were included in this review.
Results: Twenty-six of 281 patients supported with a VAD were SV. The most common diagnosis was
hypoplastic left heart syndrome (15 of 26). Nine patients were supported after neonatal palliative surgery
(Blalock-Taussig shunt or Sano), 12 after a superior cavopulmonary connection (SCPC), and 5 after total
cavopulmonary connection (TCPC). Two patients received biventricular assist devices, 1 after stage I surgery
and 1 after stage II. SV patients were supported for a median time of 10.5 days (range, 1-363 days) versus
39 days (range, 0-435 days) for BV (P ¼ .01). The ability to be bridged to transplant or recovery in SV patients
is lower than for BV patients (11 of 26 [42.3%] vs 185 of 255 [72.5%];P¼ .001). Three of 5 patients with TCPC
were successfully bridged to transplant and were supported with 1 VAD. Seven of 12 patients with SCPC were
bridged to transplant, and only 1 of 9 patients supported after a stage I procedure survived.
Conclusions: The EXCOR Pediatric VAD can provide a bridge to transplant for children with SV anatomy or
physiology, albeit less successfully than in children with BV. In this small series, results are better in patients
with SCPC and TCPC. VAD support for patients with shunted sources of pulmonary blood flow should be
applied with caution. (J Thorac Cardiovasc Surg 2014;147:697-705)Until recently, options for children listed for cardiac trans-
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The Journal of Thoracic and Cacirculatory support available for smaller children with
cardiac failure was extracorporeal membrane
oxygenation (ECMO). The frequency of complications
such as bleeding and infection, as well as the inability to
extubate or ambulate patients on ECMO makes it an
inadequate therapy for patients needing more than a few
days of support.6-8
Mortality in children treated with ECMO as a bridge to
cardiac transplantation is more than 50%,8-10 and the
subset of patients with single ventricular anatomy or
physiology (SV) fare the worst. In a multiinstitutional
review of more than 750 children supported on ECMO as
a bridge to transplant, congenital heart disease (CHD) was
the most common indication for listing (64%) and, of this
group, 30% were SV (231 patients). Patients with
cardiomyopathy had the highest survival to hospital
discharge (63%), and SV had the lowest survival at 33%.
In addition, children with a diagnosis of SV had the
poorest results compared with other diagnoses for death
on the waiting list (48%), death while on ECMO (45%),
and death after transplant and before discharge (69%).8rdiovascular Surgery c Volume 147, Number 2 697
Abbreviations and Acronyms
BiVAD ¼ biventricular assist device
BSA ¼ body surface area
BT ¼ Blalock-Taussig
BV ¼ 2-ventricle anatomy and physiology
CHD ¼ congenital heart disease
ECMO ¼ extracorporeal membrane oxygenation
FDA ¼ US Food and Drug Administration
HLHS ¼ hypoplastic left heart syndrome
IDE ¼ Investigational Device Exemption
RVAD ¼ right ventricular assist device
SV ¼ 1-ventricle anatomy and physiology
VAD ¼ ventricular assist device
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DIn contrast to ECMO support, outcomes for all children
receiving a ventricular assist device (VAD) as the bridge
modality fare significantly better.11-15 In the initial North
American experience with the Berlin Heart EXCOR
(Berlin Heart Meditechnik GmbH, Berlin, Germany),
Morales and colleagues11 found 70% success as a bridge
to transplant and 7% success as a bridge to recovery. In
addition, survival after VAD explanation and cardiac trans-
plantation is equivalent to patients receiving a transplant
without VAD support.11,13,16,17
The primary cohorts in the US Food and Drug Adminis-
tration (FDA) Investigational Device Exemption (IDE) trial
showed 90% success with the EXCOR Pediatric for
bridging to transplant or recovery15 but most children
receiving devices in the United States were excluded from
the primary cohorts, including those patients with complex
CHD and SV lesions. Including data from patients treated
under the FDA Compassionate Use Regulation, Almond
and colleagues17 compared overall survival for all patients
treated in the United States from May 2007 to December
2010. In this review, survival for 204 patents evaluated at
12 months after treatment with the EXCOR Pediatric
VAD was 75% (64% transplanted, 6% recovered, and
5% were alive with the device in place). Neurologic
dysfunction occurred in 29% of children and was the lead-
ing cause of death. Smaller patient size (<5 kg), biventric-
ular assist device (BiVAD) support and end organ function
were associated with early mortality. Less than 10% of the
patients were treated for SV, and a more detailed evaluation
of 2-ventricle lesions versus 1-ventricle lesions was not
undertaken.17
In this article, the initial, multicenter experience using the
EXCOR Pediatric to bridge patients with SV physiology is
described. In an attempt to define outcomes and practice
patterns, data from SV patients treated in the compassionate
use cohort are compared with results for patients with
2-ventricle anatomy and physiology (BV).698 The Journal of Thoracic and Cardiovascular SurgMETHODS
Twenty-six patients with an anatomic diagnosis of SVCHDwho had the
EXCOR Pediatric VAD implanted between May 2007 and December 2011
were identified from the EXCOR Pediatric IDE trial database. These pa-
tients had the device implanted under the FDA’s Compassionate Use Regu-
lation because SV lesions were listed as an exclusion criterion in the
primary cohorts of the IDE trial. For reference purposes, we compared
these patients with the 255 BV patients supported on EXCOR Pediatric
during the same time period. The data analyzed in this review were ob-
tained from the Berlin Heart EXCOR IDE trial database, which was built
on the INTERMACS Registry platform.
Statistical Methods
Data were analyzed using SAS v9.2. Categorical variables are described
using frequencies and percentiles. Continuous variables are described us-
ing medians and ranges. Statistical comparisons were made using the g2
and Fisher exact tests for categorical variables and the nonparametric
Kruskal-Wallis test for continuous variables.
Outcome data for competing events are displayed graphically using
competing outcomes methodology. Serious adverse events were reported
into the database by the participating centers. Only data from the IDE sites
were adjudicated before the submission for Humanitarian Device Exemp-
tion approval.
RESULTS
Preimplant Patient Data
The most frequently occurring diagnosis resulting in car-
diac failure requiring placement of a VADamong SV patients
was hypoplastic left heart syndrome (HLHS),which occurred
in 15 (58%) patients (Table 1). One patient with tricuspid
atresia had the EXCOR implanted with a Blalock-Taussig
(BT) shunt as the first procedure. All other SV patients had
at least 1 operation before VAD implantation; 9 (35%) after
stage I palliation, 12 (46%) after stage II palliation, and 5
(19%) after stage III palliation. One of the 9 stage I patients
with tricuspid atresia had BT shunt placement without neo-
aortic reconstruction as the first procedure. Two of the 26 pa-
tients received a BiVAD, 1 after stage I surgery and 1 after
stage II. In both cases, the pulmonary arteries were recon-
structed to allow implantation of the right ventricular assist
device (RVAD, pulmonary circulation). Systemic support
(left VAD, systemic circulation) was maintained from the
dominant ventricle to the reconstructed neoaorta. Both pa-
tients survived to transplantation. Concomitant procedures
performed in 8 of the 26 patients are also described in Table 1.
Patient demographics and clinical characteristics were
similar between the SV and BV cohorts (Table 2). Twelve
(46%) of the SV patients were on ECMO before VAD im-
plantation, similar to the 40% on ECMO before VAD im-
plantation in the BV group.
Comparedwith the BV patients, thosewith SV had higher
bilirubin and hemoglobin levels, and lower antithrombin III,
white blood cell count, and albumin levels (Table 3).
Survival
Successful bridge to cardiac transplantation or recovery
using the EXCOR Pediatric was significantly less for theery c February 2014
TABLE 1. Summary of SV patient data
Variable Palliation stage
Result,
n (% of 26)
Primary anatomic
diagnosis
Hypoplastic left heart syndrome 15 (57.7)
Unbalanced atrioventricular canal 2 (7.7)
Tricuspid atresia 1 (3.9)
Pulmonary atresia with intact
ventricular septum
1 (3.9)
Double inlet left ventricle 2 (7.7)
Ebstein’s double outlet
right ventricle
2 (7.7)
Transposition, hypoplastic
left ventricle
2 (7.7)
Palliative surgery at
time of EXCOR
implant
Stage I 9 (34.6)
Stage II 12 (46.1)
Stage III 5 (19.2)
Systemic VAD
(n ¼ 24)
Stage I 8 (30.8)
Stage II 11 (42.3)
Stage III 5 (19.2)
BiVADs (n ¼ 2) Stage I 1 (3.9)
Stage II 1 (3.9)
Stage III 0 (0.0)
Concomitant
surgeries
None 18 (69.2)
Atrial septum defect closure
and closure of aortic valve
1 (3.9)
BT shunt 1 (3.9)
Damas-Kaye-Stansel with BT shunt 1 (3.9)
Epicardial pacemaker repositioning 1 (3.9)
Glenn shunt, BT shunt takedown 1 (3.9)
Repair of diaphragmatic hernia 1 (3.9)
Repair of inominate artery injury 1 (3.9)
Repair of right internal carotid artery 1 (3.9)
VAD, Ventricular assist device;BiVAD, biventricular assist device;BT, Blalock-Taussig.
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DSV patients compared with the BV patients (42.3% vs
73.3%, c2 P¼ .001) (Table 4). No patients in the SV group
were bridged to recovery. Time to death while on VAD sup-
port for the SV patients ranged from 0 to 363 days (median
11 days). There were 11 deaths while on EXCOR, and 4
additional deaths in patients who were transitioned to
ECMO from the VAD because the device failed to support
either the cardiac or pulmonary circulations. Three of these
patients died within 30 days on ECMO. A fourth patient sur-
vived 9 days on ECMO until receiving a suitable heart, but
died 2 weeks after the transplant.
Survival among SV patients differed according to stage
of palliation before implant (Table 5). Eight of 9 patients
with an EXCOR Pediatric implant after neonatal palliation
died, all within 3 weeks of implantation (range, 0-17 days).
The only survivor in this review after stage I palliation was a
17-month-old child (Damus-Kaye-Stansel procedure) who
had a BT shunt taken down and BiVADs placed after
pulmonary artery reconstruction. Seven of 12 patients
implanted after stage II palliation were successfully trans-
planted. One of the VAD survivors with Glenn physiology
tolerated the device for 101 days before receiving a heart.The Journal of Thoracic and CaOf the 5 patients supported with EXCOR Pediatric after
the Fontan operation, 3 survived to transplantation. The 2
patients who died tolerated support for almost 1 year, and
died of multisystem organ failure and hemorrhagic stroke
at 362 and 363 days.
The median wait time on VAD support for the 11 pa-
tients who survived to transplantation was 52 days (range,
1-229 days). Although there is an early drop in survival
among the SV group compared with the BV group
(Figure 1, A and B), 63.6% (7 of 11) of the SV patients
who survived the initial 14 days after implantation were
successfully bridged to a transplant with a median wait
time of 59 days (range, 22-229 days). Figure 1, A and
B, shows competing outcomes for the SV and BV
patients.
Device Details
Fifty percent of SV patients received an implant with a
25- or 30-mL pump, whereas 38.5% of SV patients had a
10-mL pump placed. Three patients (11.5%), all more
than 30 kg, were treated with 60 mL systemic VADs. These
data are similar to the BV group. In-flow cannulae were
placed from the dominant systemic ventricular apex as in
the BV patients, except for 1 patient with common atrial
cannulation, and all outflow cannulae were placed to the
ascending aorta. Both patients who had RVADs were
cannulated from the right atrium to the pulmonary artery.
The systemic VAD stroke rate (85.0 vs 70.0 bpm,
P< .001) and systolic pressure (200.0 vs 183 mm Hg,
P ¼ .01) were higher in the SV group compared with BV
patients. Pump sizes between both groups were similar
and unrelated to mortality. The ratio of pump size to body
surface area (BSA) is also similar (SV, 45.4 (interquartile
range [IQR], 39.7-53.0); BV, 42.3 [IQR, 34.2-49.7]).
Adverse Events
Major adverse event rates were similar for the SVand BV
groups (Table 6). Among SV patients, the most common
adverse events were respiratory failure and bleeding.
The most common causes of death were reported as
multisystem organ failure in 5 patients, pulmonary/respira-
tory failure in 5 patients, cardiac failure in 2 patients, hem-
orrhage in 2 patients, and hemorrhagic cardiovascular
accident in 1 patient.
DISCUSSION
A pneumatically driven, extracorporeal, pulsatile, me-
chanical cardiac assist device specifically designed for in-
fants and small children was introduced into clinical
practice in 1992.18 The Berlin Heart EXCOR Pediatric,
built in a variety of pump sizes to accommodate patients
from a weight of 3 kg to adulthood, presented clinicians
with a viable option for children with a low BSA who
required long-term, mechanical, circulatory assistance.rdiovascular Surgery c Volume 147, Number 2 699
TABLE 2. Patient characteristics
Variable Summary 1 Ventricle (n ¼ 26) 2 Ventricles (n ¼ 255) P value
Age (mo) Median [IQR] 18.8 [4.2-46.0] 20.6 [6.4-73.1] .39*
Range 0.2-173.2 0.4-239.3
Weight (kg) Median [IQR] 10.2 [5.7-14.0] 10.8 [6.8-18.0] .24*
Range 2.8-71.0 2.9-60.0
Height (cm) Median [IQR] 75.3 [58.0-96.0] 82.0 [66.0-113.0] .17*
Range 48.0-159.0 44.0-171.0
Body surface area (m2) Median [IQR] 0.47 [0.31-0.58] 0.50 [0.36-0.74] .23*
Range 0.19-1.75 0.19-1.67
Body surface area category, n (%)
0.19-0.70 m2 23 (88.5) 182 (71.4) .06y
>0.71 m2 3 (11.5) 73 (28.6)
Gender, n (%)
Female 12 (46.2) 126 (49.4) .75y
Male 14 (53.9) 129 (50.6)
ECMO preimplant, n (%) 12 (46.2) 101 (39.6) .52y
Days on ECMO before EXCOR Median [IQR] 6.0 [4.5-7.0] 6.0 [4.0-10.0] .53*
Range 2.0-12.0 0.0-38.0
IQR, Interquartile range. *Kruskal-Wallis test. yc2 test.
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DThe availability of pumps with stroke volumes as small as
10 mL, transparent chambers that allowed for direct inspec-
tion for thrombus, and the ability to replace pumps at the
bedside have led to a considerable increase in the use of
this device in the pediatric population since 2000.6,11,15,17
The FDA approved the device in patients less than 21
years of age in December 2011, and at the time of
writing, more than 1200 EXCOR Pediatric implants had
taken place in more than 30 countries (personal
communication from Berlin Heart, Woodlands, TX).
Cardiac transplantation and mechanical support have al-
ways played a role in the treatment of CHD, but the small
case numbers compared with adults has limited evaluation
of the outcomes. Pediatric transplantation represents only
about 10% of total heart transplants performed world-
wide, and, of those, only 5% to 10% are in patients
with SV.6,19TABLE 3. Preimplant laboratory variables
Laboratory value
Bilirubin (reference range, 0.1-1.0 mg/dL)
Aspartate aminotransferase (reference range,<60 U/L)
Alanine aminotransferase (reference range, 5-30 U/L)
Blood urea nitrogen (reference range, 7-23 mg/dL)
Creatinine (reference range, 0.16-0.81 mg/dL)
Hemoglobin (reference range, 11.2-17.5 g/dL)
Platelet count (reference range, 150-350 platelets 3 103/mL)
Antithrombin III (reference range, 57%-134% activity)
Fibrinogen (reference range, 177-466 mg/dL)
Plasma-free hemoglobin (reference range,<10 mg/dL)
White blood cell count (reference range, 4.3-13.51 white blood cells 3 103/mL
Albumin (reference range, 2.9-4.7 g/dL)
Summary statistics: median [interquartile range].
700 The Journal of Thoracic and Cardiovascular SurgChildren with SV treated with mechanical assistance
represent an even smaller subset of patients, and the litera-
ture on this experience is largely limited to single-center
case reports.5,6,20-25 Use of VAD support in a patient with
a single ventricle was first reported in 2005 in an 25-year-
old man after a Fontan operation. The patient was supported
for 5 months before successful orthotopic heart transplanta-
tion.5 Use of the EXCOR Pediatric VAD was first reported
in a child with a failing single ventricle in 2006 when it was
used to support a 4-year-old girl with HLHS and a Glenn
shunt for 28 days.20
In 2009, Pearce and colleagues reported the only case in
the literature of successful use of a VAD to bridge a child
with systemic pulmonary blood flow (BT shunt) to cardiac
transplantation. A 15-month-old boy with a double outlet
right ventricle, mitral valve atresia, and D malposition of
the great vessels, developed poor systemic ventricular1 Ventricle
(n ¼ 26)
2 Ventricles
(n ¼ 255)
Kruskal-Wallis
P value
2.0 [1.1-2.7] 0.9 [0.5-1.9] .009
74.0 [56.0-197.0] 68.0 [40.0-152.0] .21
43.0 [25.0-83.0] 44.0 [20.0-115.0] .78
20.5 [15.0-38.0] 22.0 [14.0-34.5] .63
0.5 [0.3-0.7] 0.4 [0.3-0.6] .75
12.8 [11.9-13.9] 11.5 [10.2-12.6] <.001
147.5 [73.0-262.0] 166.0 [99.0-303.0] .23
59.0 [39.0-83.0] 73.0 [57.5-87.0] .06
278.0 [231.0-375.0] 308.0 [227.0-396.0] .76
27.0 [10.0-60.0] 16.0 [9.0-31.0] .14
) 7.9 [7.3-10.8] 10.7 [8.0-13.8] .02
3.2 [2.7-3.6] 3.4 [3.0-3.8] .07
ery c February 2014
TABLE 4. Support and outcome information
Variable Summary 1 Ventricle (n ¼ 26) 2 Ventricles (n ¼ 255) P value
Days of support Median [IQR] 10.5 [3-59] 39.0 [16-93] .01*
Range 0-363 0-435
Successful outcome, n (%) Transplant or weaned success 11 (42.3) 185 (72.5) .001y
Outcome details Transplant, n (%) 11 (42.3) 177 (69.4) NA
Weaned for recovery, n (%) 0 (0.0) 8 (3.1)
Death, n (%) 11 (42.3) 59 (23.1)
Transition to ECMO, death<30 d, n (%) 4 (15.4) 2 (1.2)
Transition to ECMO, transplanted, n (%) 0 (0.0) 2 (1.2)
Transition to ECMO, n (%) 0 (0.0) 2 (1.2)
Weaned because of poor prognosis, n (%) 0 (0.0) 5 (2.0)
NA, Not available. *Kruskal-Wallis test. yc2 test.
Weinstein et al Congenital Heart Disease
C
H
Dfunction after palliation with pulmonary artery banding and
was supported with a 25-mL EXCOR Pediatric VAD. Pul-
monary blood flow was initially supplied through the
banded pulmonary artery, but persistent hypoxemia necessi-
tated placement of a 5-mm systemic to pulmonary arterial
shunt. VAD support was maintained for 7 weeks before suc-
cessful transplant was performed.23 Previous to our report,
the largest review of SV patients treated with a VAD was by
Van der Pluym and colleagues26; this review comprised 10
patients treated since 1988 with 4 different forms of
support.
It is likely that the use of mechanical assistance in pa-
tients with SV will increase. The Registry of the Interna-
tional Society of Heart and Lung Transplantation report in
2010 found that currently, the most common indication
for transplant during infancy is CHD (60%).19 The Pediat-
ric Heart Transplant Society found that 36% of the diagno-
ses for children listed with CHD were for single ventricle.27
Longer waiting times for patients listed, small size, and
sensitization from previous operations with bioprosthetic
tissue may lead to earlier consideration of mechanical assis-
tance in this population, who often present with rapid circu-
latory collapse after compensated cardiac failure.6,28
The small number of patients treated in this review pre-
cludes a detailed statistical analysis; however, certain prac-
tice patterns and outcomes can begin to be described.
Although caution is recommended when considering the
use of VAD support in a patient with SV, it is clear from
this review that patients can be bridged successfully after
a superior caval anastomosis or total cavopulmonary
connection. In this first detailed review of the EXCORTABLE 5. Support time by stage of palliation among SV patients
Stage of palliation
Total number
of patients Survivors
Days EXCOR support
for survivors
Da
Stage I 9 1 57 0, 1
Stage II 12 7 5, 8, 22, 52, 59, 77, 101
Stage III 5 3 1, 3, 229
Total 26 11
The Journal of Thoracic and CaPediatric experience in patients with SV, we found that pa-
tients could be supported until a suitable heart becomes
available, but at a lower success rate than seen in patients
with 2 ventricles.
The overall success rate of 42% for bridging SV patients
to cardiac transplant in this review, although less than for
BV patients, still compares favorably with ECMO ther-
apy.8,15,29 Survival for SV patients when ECMO is used
as a bridge is 33%; VAD support is capable of providing
acceptable mechanical circulatory support for
dramatically longer time periods.15 This is a critical issue
as children with end-stage heart failure face the highest
wait list mortality of any patient waiting for a solid-organ
transplant.15 In addition, survival after VAD support is not
different from patients transplanted without a VAD,
whereas ECMO support before a cardiac transplant is a
risk factor for death.8,11,13
However, the superiority of VAD support over ECMO is
unclear when considering treating a patient after a stage I
procedure with a systemic source of pulmonary blood
flow. There were no survivors among patients treated in
the neonatal period with VAD support (3 of 9 patients),
and all deaths were early (17 days). Five additional SV pa-
tients in this cohort with a VAD and a BT shunt as the source
of pulmonary blood flow who were supported at age 2.3 to
7.3 months when they received a VAD also did not survive.
The only survivor in this review after stage I palliation was
17months out from the original surgery, and underwent pul-
monary artery reconstruction to allow BiVAD support.
There were no survivors among patients treated with VAD
support after a stage I procedure when used from theys EXCOR support
for nonsurvivors
Days on EXCOR until
conversion to ECMO
Days after conversion
to ECMO to death
, 1, 4, 10, 11, 12, 17 1 21 (2 wk after transplant)
1, 270 3, 7, 7 0, 14, 30
362, 363
rdiovascular Surgery c Volume 147, Number 2 701
FIGURE 1. A, Competing outcomes for 26 SV patients. B, Competing
outcomes for 255 BV patients.
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Doperating room as salvage therapy for failure to wean from
bypass, or when a VAD was used for failure to wean from
ECMO.
In this review, no SV patient weighing 7.0 kg or less
could be bridged to transplantation. Although younger age
and lower BSA are associated with mortality in previous
studies,11,17 this does not completely explain the dismal
outcome for stage I patients. Difficulty in selecting the
correct pump size for patients with parallel circulations,
extra sources of collateral pulmonary blood flow, and the
difficulty in balancing the systemic and pulmonary
circulations may all contribute to the unacceptable
mortality at this stage. In addition to the challenges of
managing shunt physiology on a VAD, immature
coagulation systems and technical considerations for
small patients, or another as yet unrecognized variable
that is a surrogate for size/age may also contribute to the
challenges in managing these patients. It may be
speculated that as patients can be supported with a single702 The Journal of Thoracic and Cardiovascular SurgVAD after a Glenn or Fontan procedure, converting
neonates after palliation with a systemic source (arterial
or ventricular) of pulmonary blood flow to BiVAD might
offer an improvement in outcomes.
In contrast to stage I patients, the data in this report
demonstrate that implantation of the EXCOR Pediatric after
a Glenn shunt or Fontan operation can be successful, and
effective for long-term support. Seven of 12 patients sup-
ported with EXCOR Pediatric after a Glenn shunt were
bridged to a transplant, the longest for 101 days. Patients
with total cavopulmonary connections (3 of 5) were suc-
cessfully supported to transplantation, with 1 of the survi-
vors bridged for 229 days. The 2 patients with total
cavopulmonary shunts who did not survive to transplant
were supported for362 and 363 days, suggesting that
long-term support on Berlin Heart EXCOR can be achieved
for SV patients who do not have systemic to pulmonary
arterial sources of blood flow. In the overall group, SV pa-
tients who could be supported past 14 days had an overall
success of bridge to transplantation of 63%, and all but 1
of these patients had a VAD placed after a Glen or Fontan
procedure. This is in contrast with the ECMO experience
where mortality increases steadily over time.11,17
In addition to the significant issues of low BSA, physi-
ology, and increased morbidity of patients who undergo
multiple reoperations, there are technical challenges at the
time of VAD implantation for SV patients. The apex of
the ventricular chamber can be displaced, or the most
accessible ventricle may be a smaller chamber with an
awkward communication to a larger ventricle.6,26 Several
surgeons have recommended using transesophageal
echocardiography guidance to assist in finding the correct
chamber at the time of surgery. Coronary anatomy and
other key landmarks at surgery may be obscured by
reoperative adhesions. VAD placement after a Fontan
operation may require reconstruction of the pulmonary
arteries and venous capacitance chamber(s), as well as
closure of the fenestration if present. In addition, chronic
exposure of most of these patients to cyanosis, hepatic
and renal insufficiency, as well as abnormalities in
coagulation contribute to a potentially more challenging
perioperative period.
The improved success observed recently compared with
ECMO has translated to a considerable increase in the use
of the EXCOR Pediatric VAD since 2005.17 In the setting
of improved survival for palliative surgery for all forms of
single ventricle and increasing waiting list times for chil-
dren who develop cardiac failure, VAD therapy may be a
more attractive option than ECMO for patients with supe-
rior or total cavopulmonary anastomosis.
Study Limitations
This study has several limitations beyond its description
of the initial experience of the EXCOR Pediatric in SVery c February 2014
TABLE 6. Event summary
Events occurring while on EXCOR
device support
1 Ventricle (n ¼ 26) 2 Ventricles (n ¼ 255)
Patient with
event,% of 26
(95% CI)
Total events
(rate per 100
patient-days)
Patient with
event,% of 255
(95% CI)
Total events (rate per
100 patient-days)
Any serious adverse event 73.1 (56.0, 90.1) 82.8 (78.1, 87.4)
Major bleeding event 38.5 (19.8, 57.2) 14 (0.85) 44.3 (38.2, 50.4) 194 (1.15)
Hypertension event 11.5 (0.7, 23.8) 4 (0.24) 26.7 (21.2, 32.1) 73 (0.43)
Major infection event 23.1 (6.9, 39.3) 21 (1.28) 34.1 (28.3, 39.9) 239 (1.42)
Neurologic dysfunction 15.4 (1.5, 29.3) 4 (0.24) 17.3 (12.6, 21.9) 49 (0.29)
Arterial noncentral nervous system thromboembolism 0.0 (0.0, 0.0) 0 (0.00) 2.7 (0.7, 4.8) 7 (0.04)
Venous thromboembolism 0.0 (0.0, 0.0) 0 (0.00) 2.0 (0.3, 3.7) 5 (0.03)
Renal dysfunction event, acute 11.5 (0.7, 23.8) 3 (0.18) 9.8 (6.2, 13.5) 28 (0.17)
Renal dysfunction event, chronic 0.0 (0.0, 0.0) 0 (0.00) 0.8 (0.3, 1.9) 2 (0.01)
Respiratory failure 42.3 (23.3, 61.3) 15 (0.92) 27.1 (21.6, 32.5) 90 (0.53)
Pump change due to thrombus 26.9 (9.9, 44.0) 21 (1.28) 40.4 (34.4, 46.4) 194 (1.15)
Total time of support was 1683 days for 1 ventricle and 16,843 days for 2 ventricles.
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Dpatients. The small number of cases precludes potential sta-
tistical comparisons with non-SV VAD controls. The lack
of randomization, although not practical considering the
limits of other therapies, means comparing outcomes with
historical controls of patients treated with ECMO. In addi-
tion, not all serious adverse events were adjudicated
because of the inclusion of data from non-IDE trial sites.CONCLUSIONS
VADs in SV patients, although less successful than in pa-
tients with 2 ventricles, can still be used as a successful
bridge to cardiac transplantation. The use of VADs has
been more successful in patients with partial or total cavo-
pulmonary shunts than in neonates after a Norwood proce-
dure or with other lesions with shunt-dependent pulmonary
blood flow. Whether this is due to patient BSA, age, physi-
ology, or an undiscovered surrogate variable may be uncov-
ered in a larger series. VAD therapy in children with SV
after neonatal palliation does not seem to offer any signifi-
cant advantages over ECMO therapy, and should be applied
with caution.References
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Dr David L. Morales (Cincinnati, Ohio). Sam, I want to
congratulate you on a wonderful presentation and really all the au-
thors on an article that will serve as a great reference to our spe-
cialty and growing interest in VAD therapy in children.
Now, the inability to support stage I patients with a VAD really
highlights the use of salvage VADs, which are VADs used after an
unsuccessful palliation, with these patients subsequently going to
ECMO then a VAD. This type of patient has been shown repeat-
edly in many studies to have extremely poor results regardless of
a single-ventricular or a biventricular physiology. Trying to
salvage a failed Norwood is just the extreme example of salvage
VADs, and it is why their outcomes here are so poor with 89%
mortality.
I have 3 questions regarding this group.
Of the stage I patients who were supported during the neonatal
period, how many were on ECMO then a VAD or on a VAD
switched to ECMO?
The second question is: What was the time from operation to
VAD for the stage I group?
And 3, was any Norwood discharged from the intensive care
unit or home before moving to a VAD?
DrWeinstein. David, thank you very much for your comments
and your questions. Your expertise in this field is well recognized,
and I have greatly appreciated your advice and personal insight as
we have established our own assistance program at my institution.
Four of the 5 neonates who had a VAD implanted were patients
who were already on ECMO. There was 1 neonate whose first sur-
gery was an LVAD and a BT shunt, but this patient was converted704 The Journal of Thoracic and Cardiovascular Surgto ECMO in the operating room for failure to support the cardiac
circulation. All stage I patients in this review regardless of age
were on ECMO before placement of the device.
Unfortunately, we do not have the information on previous sur-
geries or discharge data. However, regarding the patients who had
a VAD implanted within 30 days of life, I think we can infer that
their palliative procedures, ECMO, and subsequent VAD were
all in close proximity. As well, there were 3 stage I patients who
were aged 7 months, 8 months, and 17 months at the time of
VAD implantation, and it may also be inferred that some of these
patients were discharged home or at least achieved some form of
stability before placement of their mechanical assist device.
Dr Morales. Even with the Glenn cohort, a Glenn who fails in
the first few days after surgery is much different than a Glenn who
goes home and comes back with a failing systemic ventricle. The
Glenn that goes home and returns should be able to be successfully
supported, where the one that immediately fails in the intensive
care unit again is a salvage VAD and probably would not do
well. So with regard to this group, what was the time from Glenn
to VAD for survivors and nonsurvivors?
And 2, did any of the Glenns go home and return for their VAD,
and what was their survival compared with thosewho never left the
hospital?
DrWeinstein. The Berlin Heart database does not have the data
on the timing of any procedures performed before the VAD, but the
median age of patients undergoing a VAD implant with Glenn
shunt physiology was 2 years, and the oldest patient was 13 years.
For similar reasons, I assume several of these patients left the hos-
pital, some for perhaps a significant amount of time. So I think that
these data support your presumption that the further out you are
from any one of your staged palliations, the more likely you are
to survive VAD support.
Dr Morales. And just a final comment. Single-ventricle pa-
tients are not different than other congenital patients and a failed
palliation supported with a VAD will probably result in poor out-
comes; however, the single-ventricle physiology just emphasizes
this point.
Having said that, VAD therapy in patients who have systemic-
to-pulmonary shunt and the late-failing Fontan are unique chal-
lenges compared with other single-ventricle patients and ones
that we will have to continue to investigate I think. But again,
you and your authors have given us a great first step with this
article. Thank you.
Dr Christopher A. Caldarone (Toronto, Ontario, Canada).
Sam, could you comment a little bit on the overall interpretation
of your presentation. I mean, it sounds quite dismal in terms of
the concept of mechanical support for the failing single ventricle,
but that may be a function of some immutable bit of physiology
among single-ventricle patients or it may be that we are just too
slow to pull the trigger and go to mechanical support. This is a de-
cision we wrestle with constantly. And can you get any insights
from the data that you have here?
Dr Weinstein. I think that success is related as much to age as
to stage, and I am not sure which variable is the most important.
There were 4 patients who were supported with ECMO before
VAD implantation who were not shunted patients, 2 Glenns
and 2 Fontans. And 3 of those 4 survived. So I think that for ne-
onates and for shunted patients, and as a salvage procedure, itery c February 2014
Weinstein et al Congenital Heart Diseasedoes not seem, from this small group only, that it would be war-
ranted. But I do think for older patients, patients that may be
further out from stage II or stage III palliation, it is very much
worth considering.
Dr Pedro J. del Nido (Boston, Mass). Do you have any infor-
mation about, especially focusing on the neonatal group, the
need for CPR before any mechanical support, either ECMO or ifThe Journal of Thoracic and Cayou went straight to a VAD? Do you have any data about that
group? Because I would think that need for CPRmay be the trigger
point for you to decide whether you are going to put a child on this
long-term assist or not.
DrWeinstein. That is an excellent point. Unfortunately, the in-
formation about CPR or other status before ECMO implant is
anecdotal.rdiovascular Surgery c Volume 147, Number 2 705
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